Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer

Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.

Who May Be Eligible (Plain English)

Who May Qualify: - histologically verified lung cancer (small-cell and non-small cell lung cancer) - referred for radiotherapy with curative intent - radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard - concurrent chemotherapy is accepted - patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy - receiving (chemo)-radiotherapy to the thoracic disease with curative intent - adults over 18, that have given oral and written willing to sign a consent form before patient registration. Who Should NOT Join This Trial: - concurrent immunotherapy - previous radiotherapy to the thorax - other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * histologically verified lung cancer (small-cell and non-small cell lung cancer) * referred for radiotherapy with curative intent * radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard * concurrent chemotherapy is accepted * patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy * receiving (chemo)-radiotherapy to the thoracic disease with curative intent * adults over 18, that have given oral and written informed consent before patient registration. Exclusion Criteria: * concurrent immunotherapy * previous radiotherapy to the thorax * other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol

Treatments Being Tested

DIAGNOSTIC_TEST

Single-photon-emission CT scan

SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung

Locations (2)

Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals
Sydney, New South Wales, Australia
Department of Oncology, Aarhus University Hospital
Aarhus, Denmark